Holdings
Trails Edge Capital Partners, LP
As of Jun 30, 2026, Trails Edge Capital Partners, LP reported 32 positions worth US$571M. Largest: Lb Pharmaceuticals Inc, Nurix Therapeutics, Inc. and First Tracks Biotherapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Lb Pharmaceuticals Inc | 1.52M | US$49.4M | +204K | Jun 30, 2026 |
| Nurix Therapeutics, Inc. | 1.57M | US$38.2M | −170K | Jun 30, 2026 |
| First Tracks Biotherapeutics, Inc. | 1.51M | US$30.5M | new | Jun 30, 2026 |
| 4d Molecular Therapeutics, Inc. | 2.23M | US$29.6M | +925K | Jun 30, 2026 |
| Biomarin Pharmaceutical Inc. | 512K | US$29.3M | new | Jun 30, 2026 |
| Design Therapeutics, Inc. | 2M | US$29M | +1.15M | Jun 30, 2026 |
| Xenon Pharmaceuticals Inc. | 440K | US$26.6M | no change | Jun 30, 2026 |
| Mirum Pharmaceuticals, Inc. | 223K | US$26.1M | −110K | Jun 30, 2026 |
| Insmed Incorporated | 230K | US$24.6M | new | Jun 30, 2026 |
| Cytokinetics, Incorporated | 288K | US$24.5M | −11,911 | Jun 30, 2026 |